Drug Type siRNA |
Synonyms RBD-4059, RBD4059, SR059 |
Target |
Action inhibitors |
Mechanism F11 inhibitors(Coagulation factor XI inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Coronary Artery Disease | Phase 2 | Sweden | 28 Aug 2024 | |
Thromboembolism | Phase 2 | Sweden | - | |
Coronary Disease | IND Approval | European Union | 29 May 2024 | |
Thrombosis | IND Approval | Australia | 06 Feb 2023 | |
Kidney Failure, Chronic | Preclinical | China | - | |
Upper Extremity Deep Vein Thrombosis | Preclinical | China | - |
NCT05653037 (NEWS) Manual | Phase 1 | - | - | ckngbzuzwa(xzojkyiinj) = RBD4059呈现出剂量依赖性、可预测的药代动力学特性,以及显著的(>90%)和持久的FXI活性和蛋白质降低效果。其在每3个月或6个月的给药方案中保持了高水平的药效学(PD)效果,有望在慢性抗凝治疗中实现更高依从性、和更低的出血风险。 ssubwdwori (ndllgfhjnx ) View more | Positive | 31 Aug 2024 | |
Phase 1 | - | - | cufjnrcafh(ftiozssboi) = RBD4059 was well tolerated, all related AEs were grade 1. There was no evidence of any clinically relevant bleeding events gcwxjgnbtv (pzrptnunjg ) View more | - | 31 Aug 2024 | ||